Order Online! Now! Get your $50 coupon for online order.
Order Online! Now! Get your $50 coupon for online order.
Our limited edition HOLIDAYS LLAMA is here! Place any order now to recieve one!
Earn Loyalty Rewards! Up to $155 Amazon Gift Card
Time Limited Offer: Welcome Gift for New Customers !
Time Limited Offer: Welcome Gift for New Customers !
Project item | Indications | Research phase | Cooperation demands |
BSB202301 | Solid Tumor (Lung Cancer) | Phase 1b/2a (USA, KR) | Global and Regional Out-licensing |
BLL202202 | broad cancer | Ready for CMC development | License-out or co-development |
BEX202202 | Advanced solid tumor | Preclinical | License-out or co-development |
BBS21008 | Solid tumors such as lung cancer, gastric carcinoma, esophagus cancer, cervical cancer. | Pre-clinical, CMC developing; | Project transfer or co-development. (the project’s company is in the startup stage and seek external cooperation to accelate drug research and development.) |
Expression analysis of human PD-1 on Human PD-1 (Luc) Jurkat Reporter Cell by FACS.
Human PD-1 (Luc) Jurkat Reporter Cell or negative control cell were stained with FITC-labeled anti-human PD1 antibody.
Rabbit PD-L1, His Tag (Cat. No. PDL-R52H6) immobilized on CM5 Chip can bind Rabbit PD-1, His Tag (Cat. No. PD1-R52H0) with an affinity constant of 3.87 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Zimberelimab | AB-122; GLS-010; WBP-3055 | Approved | Harbin Gloria Pharmaceuticals Co Ltd, Wuxi Biologics (Shanghai) Co Ltd | 誉妥 | Mainland China | Hodgkin Disease | Guangzhou Yuheng Biotechnology Co Ltd | 2021-08-25 | Urinary Bladder Neoplasms; Adenocarcinoma; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Lymphoma, Non-Hodgkin; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Lung Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Multiple Myeloma; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Pancreatic Neoplasms; Glioblastoma; Triple Negative Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Ovarian Neoplasms; Liver Neoplasms | Details |
Penpulimab | AK-105 | Approved | 安尼可 | Mainland China | Hodgkin Disease | Zhengda Tianqing Kangfang (Shanghai) Biomedical Technology Co Ltd | 2021-08-03 | Neuroendocrine Tumors; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell; Lung Neoplasms; Urologic Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Microsatellite instability-high cancer; Hodgkin Disease; Neoplasms; Esophageal Neoplasms; Thoracic Neoplasms; Head and Neck Neoplasms; Liver Neoplasms | Details | |
Toripalimab | JS-001sc; TAB-001; JS-001; SO-001 | Approved | 拓益 | Mainland China | Carcinoma, Non-Small-Cell Lung | Shanghai Junshi Biosciences Co Ltd | 2018-12-17 | Lymphoma; Urinary Bladder Neoplasms; Rejection of organ transplantation; Nasopharyngeal Carcinoma; Breast Neoplasms; Sarcoma; Cholangiocarcinoma; Urologic Neoplasms; Colorectal Neoplasms; Neuroendocrine Tumors; Esophageal Squamous Cell Carcinoma; Epstein-Barr Virus Infections; Laryngeal Neoplasms; Lung Neoplasms; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Stomach Neoplasms; Solid tumours; Colorectal Neoplasms, Hereditary Nonpolyposis; Head and Neck Neoplasms; Biliary Tract Neoplasms; Esophageal Neoplasms; Anus Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Kidney Neoplasms; Pain; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Nasopharyngeal Neoplasms; Nasopharyngeal Diseases; Hypopharyngeal Neoplasms | Details | |
Prolgolimab | BCD-100 | Approved | Biocad | Forteca | Russian Federation | Melanoma | Biocad | 2020-04-01 | Carcinoma, Renal Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms | Details |
Sintilimab | IBI-308 | Approved | Innovent Biologics(Suzhou) Co Ltd | Tyvyt, 达伯舒 | Mainland China | Stomach Neoplasms | Innovent Biologics(Suzhou) Co Ltd | 2018-12-24 | Sarcoma; Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Neoplasms, Unknown Primary; Lymphoma, Non-Hodgkin; Lung Neoplasms; Carcinoma, Neuroendocrine; Colorectal Neoplasms; Lymphoma, Extranodal NK-T-Cell; Solid tumours; Lung Diseases; Respiratory Tract Diseases; Hodgkin Disease; Nasopharyngeal Neoplasms; Neoplasms; Thoracic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Lymphoma, T-Cell, Peripheral | Details |
Cemiplimab | REGN-2810; SAR-439684 | Approved | Regeneron Pharmaceuticals Inc | Libtayo | United States | Carcinoma, Squamous Cell | Regeneron Pharmaceuticals Inc | 2018-09-28 | Sarcoma; Carcinoma, Hepatocellular; Mycosis Fungoides; Uterine Cervical Neoplasms; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung; Glioma; Mouth Neoplasms; Fallopian Tube Neoplasms; Lymphoma; Carcinoma, Squamous Cell; Diffuse Intrinsic Pontine Glioma; Peritoneal Neoplasms; Prostatic Neoplasms; Hepatitis B; Solid tumours; Central Nervous System Neoplasms; Multiple Myeloma; Papillomavirus Infections; Skin Neoplasms; Hodgkin Disease; Carcinoma, Transitional Cell; Neoplasms; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Hemangiosarcoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; HIV Infections; Ovarian Neoplasms | Details |
Pucotenlimab | AK-103; HX-008 | Approved | Taizhou Hanzhong Biomedical Co Ltd, Hanx Biopharmaceutical Co Ltd, Lepu Biotech Co Ltd | 普佑恒 | Mainland China | Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer | Lepu Biotech Co Ltd | 2022-07-19 | Solid tumours; Mismatch Repair Deficient Cancer; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Thyroid Carcinoma, Anaplastic; Triple Negative Breast Neoplasms; Microsatellite instability-high cancer; Urinary Bladder Neoplasms; Colorectal Neoplasms; Melanoma; Adenocarcinoma; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
Nivolumab/Relatlimab | BMS-986213; BMS-936558/BMS-986016 | Approved | Bristol-Myers Squibb Company | OPDUALAG | United States | Melanoma | Bristol-Myers Squibb Company | 2022-03-18 | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Colorectal Neoplasms; Melanoma | Details |
Cadonilimab | AK-104 | Approved | 开坦尼 | Mainland China | Uterine Cervical Neoplasms | Kangfang Pharmaceutical Co Ltd | 2022-06-29 | Nasopharyngeal Carcinoma; Melanoma; Carcinoma, Hepatocellular; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; DNA Repair-Deficiency Disorders; Colorectal Neoplasms; Urologic Neoplasms; Microsatellite Instability; Lymphoma, T-Cell, Peripheral; Microsatellite instability-high cancer; Triple Negative Breast Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Carcinoma; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Solid tumours | Details | |
Dostarlimab | WBP-285; TSR-042; ANB-011 | Approved | Anaptysbio Inc | JEMPERLI | EU | Endometrial Neoplasms | Glaxosmithkline (Ireland) Ltd | 2021-04-21 | Sarcoma, Clear Cell; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Lung Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Solid tumours; Breast Neoplasms; Gestational Trophoblastic Disease; Mesothelioma; Colonic Neoplasms; Pancreatic Neoplasms; Neoplasms; Rectal Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms | Details |
Serplulimab | HLX-10 | Approved | Shanghai Henlius Biotech Inc | 汉斯状 | Mainland China | Microsatellite instability-high cancer | Shanghai Henlius Biopharmaceuticals Co Ltd | 2022-03-22 | Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Colorectal Neoplasms; Microsatellite Instability; Microsatellite instability-high cancer; Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Hepatitis B, Chronic; Carcinoma; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Head and Neck Neoplasms; Liver Neoplasms | Details |
Nivolumab | BMS-936558-01; MDX-1106; ONO-4538; ono-0123; BMS-936558 | Approved | Bristol-Myers Squibb Company, Ono Pharmaceutical Co Ltd | Opdivo, 欧狄沃 | Japan | Melanoma | Ono Pharmaceutical Co Ltd | 2014-07-04 | Leukemia, Myelogenous, Chronic; Ovarian Neoplasms; Biliary Tract Neoplasms; Medulloblastoma; Ependymoma; Liver Neoplasms; Solid tumours; Hematologic Neoplasms; Lymphoma, T-Cell, Peripheral; Head and Neck Neoplasms; Hematopoietic stem cell transplantation (HSCT); Tobacco Smoking; Acquired Immunodeficiency Syndrome; Leiomyosarcoma; Kidney Neoplasms; Drug-Related Side Effects and Adverse Reactions; Bone Marrow Neoplasms; HIV Infections; Stomach Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Anus Neoplasms; Leukemia, Lymphoid; Giant Cell Arteritis; Dermatomyositis; Inflammatory Bowel Diseases; Mismatch Repair Deficient Cancer; Leukoplakia, Oral; Thoracic Neoplasms; Polycythemia Vera; Carcinoma, Merkel Cell; Neoplasms; Leukemia-Lymphoma, Adult T-Cell; Carcinoma, Transitional Cell; Arthritis, Rheumatoid; Hodgkin Disease; Skin Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Neoplasms; Colonic Neoplasms; Gliobla | Details |
Tislelizumab | BGB-A317; VDT-482 | Approved | Beigene Ltd | 百泽安 | Mainland China | Hodgkin Disease | Beigene (Shanghai) Biotechnology Co Ltd | 2019-12-26 | Lymphoma, Large-Cell, Anaplastic; Digestive System Neoplasms; Nasopharyngeal Carcinoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Extranodal NK-T-Cell; Cholangiocarcinoma; Colorectal Neoplasms; Thymoma; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Urinary Bladder Neoplasms; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell; Lymphoma; Metastatic breast cancer; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Melanoma; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Mismatch Repair Deficient Cancer; Skin Melanoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, T-Cell, Peripheral; Leukemia; Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Renal Cell; Anus Neoplasms; Stomach Neoplasms; Solid tumours; Rectal Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Neoplasms; Small Cell Lung Carcinoma; Mesothelioma; Microsatellite instability | Details |
Camrelizumab | SHR-1210; INCSHR-1210; HR-301210 | Approved | Jiangsu Hengrui Medicine Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd | 艾立妥, 艾瑞卡, AiRuiKa | Mainland China | Hodgkin Disease | Suzhou Suncadia Biopharmaceuticals Co Ltd | 2019-05-29 | Endometrial Neoplasms; Lymphoma, Extranodal NK-T-Cell; Cholangiocarcinoma; Breast Neoplasms; Respiratory Tract Neoplasms; Genital Neoplasms, Female; Urologic Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Lymphoma; Carcinoma, Squamous Cell; Lung Neoplasms; Sarcoma; Paranasal Sinus Neoplasms; Esophageal adenocarcinoma; Uterine Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Esophageal Diseases; Neoplasm Metastasis; Gastrointestinal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Ovarian Neoplasms; Liver Neoplasms; Biliary Tract Neoplasms; Hemorrhagic Fever, Ebola; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Thoracic Neoplasms; Bronchial Neoplasms; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Triple Negative Breast Neoplasms; Neoplasms; Nasopharyngeal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Transitional Cell; Hodgkin Disease; Hypopharyngeal Neoplasms; Lung Diseases; Urinary Bladder N | Details |
Pembrolizumab | SCH-900475; h409A11; MK-3475 | Approved | Merck & Co Inc | 可瑞达, Keytruda | United States | Melanoma | Merck Sharp & Dohme Corp | 2014-09-04 | Solid tumours; Head and Neck Neoplasms; Liver Neoplasms; Hematologic Neoplasms; Ovarian Neoplasms; Lymphoma, B-Cell; Solitary Fibrous Tumor, Pleural; Kidney Neoplasms; Biliary Tract Neoplasms; Neoplasm Recurrence, Local; Lymphoma, T-Cell, Peripheral; Erythema; Neoplasm, Residual; Lymphoma, B-Cell, Marginal Zone; HIV Infections; Bone metastases; Intestinal Neoplasms; Leiomyosarcoma; Ovarian germ cell tumor; Colorectal Neoplasms, Hereditary Nonpolyposis; Ependymoma; Medulloblastoma; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Merkel Cell; Spinal Cord Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Anus Neoplasms; Vaginal Diseases; Carcinoid Tumor; Polycythemia Vera; Mismatch Repair Deficient Cancer; Vaginitis; Cystadenocarcinoma, Serous; Genital Neoplasms, Male; Pheochromocytoma; Rectal Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Neoplasms; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Hodgkin Disease; Skin Neoplasms; Small Cel | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
INCA-32459 | INCA-32459 | Phase 1 Clinical | Incyte Corp, Merus Nv | Neoplasms | Details |
Peramprizumab | Phase 2 Clinical | Sun Yat-Sen University | Nasopharyngeal Carcinoma | Details | |
EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania) | LXF-821 | Phase 1 Clinical | University Of Pennsylvania, Novartis Pharma Ag | Glioblastoma | Details |
TC-510 | TC-510 | Phase 2 Clinical | Tcr2 Therapeutics Inc | Solid tumours; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Mesothelioma; Colorectal Neoplasms; Adenocarcinoma | Details |
ONO-4685 | ONO-4685 | Phase 1 Clinical | Merus Nv | Psoriasis; Lymphoma, T-Cell | Details |
Rosnilimab | ANB-030 | Phase 2 Clinical | Anaptysbio Inc | Alopecia Areata | Details |
IAP-0971 | IAP-0971 | Phase 2 Clinical | Shenghe (China) Biopharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
Anti-CTLA-4/PD-1 expressing EGFR-CAR-T | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Solid tumours | Details | |
Anti-PD1/anti-TIM3 bispecific antibody (L&L vision biopharmaceuticals) | Bis-5 | Phase 1 Clinical | L&L Biopharma Co Ltd | Neoplasms | Details |
TY-101 | TY-101; TY101 | Phase 2 Clinical | Tayu Huaxia Biotech Medical Group Co Ltd | Solid tumours; Lymphoma | Details |
SSGJ-706 | SSGJ-706 | Phase 1 Clinical | Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd | Solid tumours; Lymphoma | Details |
SSI-361 | LVGN-3616; SSI-361 | Phase 2 Clinical | Lyvgen Biopharma(HK)Ltd | Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Papillomavirus Infections; Neoplasms; Uveal melanoma; Sarcoma; Carcinoma, Hepatocellular; Neoplasm Metastasis | Details |
RO-7121661 | RG-7769; RO-7121661 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Small Cell Lung Carcinoma; Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
ONCR-177 | ONCR-177 | Phase 1 Clinical | Oncorus Inc | Solid tumours; Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Skin Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma | Details |
SSGJ-705 | SSGJ-705 | Phase 1 Clinical | Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd | Solid tumours; Neoplasms | Details |
RG-6279 | RG-6279 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours | Details |
JS-201 | JS-201 | Phase 1 Clinical | Neoplasms | Details | |
LBL-015 | LBL-015 | Phase 2 Clinical | Nanjing Leads Biolabs Co Ltd | Solid tumours | Details |
Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Neoplasms | Details | |
Pimivalimab | JTX-4014 | Phase 2 Clinical | Jounce Therapeutics Inc | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
PD-1 knockout engineered T cells (Chengdu MedGenCell) | Phase 2 Clinical | West China Hospital Of Sichuan University, Chengdu Medgencell | Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma | Details | |
RB-0004 | RB-0004 | Phase 1 Clinical | Reyoung Pharmaceutical Co Ltd | Solid tumours; Lymphoma | Details |
Zeluvalimab | AMG-404 | Phase 2 Clinical | Amgen Inc | Solid tumours; Small Cell Lung Carcinoma; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms | Details |
PF-07209960 | PF-07209960 | Phase 1 Clinical | Pfizer Inc | Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
EBV-specific TCR-T cell with anti-PD1 auto-secreted element | Phase 2 Clinical | Tcrcure Biopharma Ltd | Squamous Cell Carcinoma of Head and Neck | Details | |
CC-90006 | C-90006; CC-90006 | Phase 1 Clinical | Anaptysbio Inc | Autoimmune Diseases; Psoriasis | Details |
Taminadenant | NIR-178; PBF-509 | Phase 2 Clinical | Palobiofarma Sl | Head and Neck Neoplasms; Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Carcinoma; Triple Negative Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Colorectal Neoplasms; Parkinson Disease; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) | ICTCAR-014 | Phase 2 Clinical | Innovative Cellular Therapeutics Co Ltd | Lymphoma, Non-Hodgkin | Details |
Multiple target antigen stimulating cell therapy (HengRui YuanZheng Biotechnology) | Phase 2 Clinical | Hengrui Yuanzheng (Shanghai) Biotechnology Co Ltd | Solid tumours; Liver Neoplasms; Stomach Neoplasms; Neoplasms; Liver Diseases | Details | |
BAT-1308 | BAT-1308 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
Tebotelimab | PD-1 X LAG-3; MGD-013 | Phase 3 Clinical | Macrogenics Inc | Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Adenocarcinoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Endometrial Neoplasms; Cholangiocarcinoma; Small Cell Lung Carcinoma; Liver Neoplasms; Triple Negative Breast Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Biliary Tract Neoplasms; Ovarian Neoplasms; Hematologic Neoplasms; Head and Neck Neoplasms; Solid tumours | Details |
YH-008 | YH-008 | Phase 1 Clinical | Eucure Pharmaceutical Technology (Beijing) Co Ltd | Solid tumours; Hematologic Neoplasms; Neoplasms | Details |
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) | Phase 2 Clinical | People'S Liberation Army General Hospital Military Service | Multiple Myeloma | Details | |
CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital) | Phase 2 Clinical | Pla General Hospital | Lymphoma, B-Cell | Details | |
89Zr-N-sucDf-pembrolizumab | Phase 1 Clinical | Merck & Co Inc, Umcg The University Medical Center Groningen | Melanoma; Carcinoma, Non-Small-Cell Lung | Details | |
CD-200-AR-L | CD-200-AR-L; hP-1-A-8 | Phase 1 Clinical | University Of Minnesota | Glioblastoma | Details |
Latikafusp | AMG-256 | Phase 1 Clinical | Amgen Inc | Solid tumours; Neoplasms | Details |
Recombinant humanized anti-PD-1 monoclonal antibody (Anhui Anke Biotechnology) | Phase 2 Clinical | Anhui Anke Biotechnology (Group) Co Ltd | Esophageal Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Lymphoma; Lung Neoplasms | Details | |
Budigalimab | ABBV-181 | Phase 2 Clinical | Abbvie Inc | Solid tumours; HIV Infections; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
QL1604 | QL1604; QL-1604 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Liver Neoplasms; Solid tumours; Neoplasms; Uterine Cervical Neoplasms; Adenocarcinoma; Carcinoma, Hepatocellular | Details |
ABBV-1882 | ABBV-1882 | Phase 1 Clinical | Abbvie Inc | HIV Infections | Details |
MAX-10181 | MAX-10181; MAX-1 | Phase 1 Clinical | Solid tumours; Neoplasms | Details | |
Acrixolimab | YBL-006; YBL 006 | Phase 2 Clinical | Y-biologics Inc | Solid tumours; Neoplasms | Details |
RO-7284755 | RO-7284755 | Phase 1 Clinical | F. Hoffmann-La Roche Ag | Solid tumours; Neoplasms | Details |
MiHA-loaded PD-L silenced DC vaccination (Radboud University) | Phase 2 Clinical | Radboud University Nijmegen | Hematologic Neoplasms; Colorectal Neoplasms | Details | |
Sym-021 | Sym-021 | Phase 1 Clinical | Symphogen A/S | Solid tumours; Lymphoma; Neoplasm Metastasis | Details |
SHR-1901 | SHR-1901 | Phase 1 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd | Neoplasms | Details |
BA1104 | LY-01015; BA-1104 | Phase 1 Clinical | Luye Pharma Group Ltd | Liver Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Mesothelioma; Urinary Bladder Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
Sym-024 | Sym-024; S-95024 | Phase 1 Clinical | Symphogen A/S | Solid tumours; Neoplasm Metastasis | Details |
TQB-2868 | TQB-2868 | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Neoplasms | Details |
Recombinant human anti-PD-1 monoclonal antibody(Hec Biological) | Phase 1 Clinical | Dongguan City Hec Biological Medicine Res And Development Co Ltd | Stomach Neoplasms; Esophageal adenocarcinoma | Details | |
T3011 | MVR-T3011; T3011; MVR-T3011 IT; MVR-T3011 IV | Phase 2 Clinical | Immvira Co Ltd | Breast Neoplasms; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Endometrial Neoplasms; Lymphoma; Lung Neoplasms; Colorectal Neoplasms; Solid tumours; Sarcoma; Mesothelioma; Skin Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Head and Neck Neoplasms; Ovarian Neoplasms; Liver Neoplasms | Details |
BI-1387446 | Phase 1 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Neoplasms | Details | |
ZG-005 | ZG-005 | Phase 2 Clinical | Solid tumours | Details | |
EMB-02 | EMB-02 | Phase 2 Clinical | Shanghai Epimab Biotherapeutics, Inc | Solid tumours; Neoplasms | Details |
PD-1 knockout EBV-CTL (Nanjing Medical University) | Phase 2 Clinical | Nanjing Medical University | Stomach Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Neoplasms; Lymphoma | Details | |
Recombinant human PD-1 antibody herpes simplex virus | Phase 1 Clinical | Yangsheng Tang Co Ltd, Xiamen University | Solid tumours; Liver Neoplasms; Head and Neck Neoplasms; Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Central Nervous System Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Brain metastases; Melanoma; Uterine Cervical Neoplasms | Details | |
IMU-201 | IMU-201 | Phase 1 Clinical | Imugene Ltd | Adenocarcinoma of Lung; Carcinoma, Large Cell; Carcinoma, Squamous Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
HerinCAR-PD1 | Phase 2 Clinical | Ningbo Cancer Hospital | Solid tumours | Details | |
CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital Of Zhejiang University School Of Medicine | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma | Details | |
Finotonlimab | SCT-I10A | Phase 3 Clinical | SinoCelltech Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Lymphoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
KY-0118 | KY-0118; KY0118 | Phase 1 Clinical | Shanghai Keyi Pharmaceutical Technology Co Ltd | Solid tumours; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
STW204 | STW-204; AI025; AI-025 | Phase 1 Clinical | Suzhou Stainwei Biotech Inc | Solid tumours; Neoplasms | Details |
JNJ-67484703 | JNJ-67484703; JNJ-4703 | Phase 1 Clinical | Janssen Research & Development Llc | Arthritis, Rheumatoid | Details |
Recombinant humanized anti-PD-1 monoclonal antibody (Shanxi Wichida Bright Pharmaceutical) | Phase 1 Clinical | Shanxi Weiqidaguangming Pharmaceutical Co Ltd | Solid tumours | Details | |
INSIX RA (Indus Biotech) | Clinical | Indus Biotech Pvt Ltd | Arthritis, Rheumatoid; Inflammation | Details | |
VT1093 | VT1093; VT-1093 | Phase 1 Clinical | Beijing Weiyuan Likang Biotechnology Co Ltd | Solid tumours | Details |
CMAB-819 | CMAB8-19 | Phase 1 Clinical | Sinomab Bioscience Ltd | Squamous Cell Carcinoma of Head and Neck; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
GNR-051 | GNR-051 | Phase 1 Clinical | Generium Pharmaceuticals | Carcinoma, Renal Cell; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
IBI-363 | IBI-363 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms; Lymphoma | Details |
Pegylated recombinant human granulocyte colony stimulating factor(Sun Yat-sen University) | Phase 1 Clinical | Sun Yat-Sen University | Nasopharyngeal Carcinoma | Details | |
Treprilimab | Clinical | Sun Yat-Sen University | Oropharyngeal Neoplasms | Details | |
Sasanlimab | PF-06801591; PF-6801591; RN-888 | Phase 3 Clinical | Pfizer Pharmaceuticals Ltd (China) | Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Endometrial Neoplasms; Carcinoma, Squamous Cell; Colorectal Neoplasms; Bile Duct Neoplasms; Prostatic Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Carcinoma, Transitional Cell; Solid tumours; Pancreatic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Carcinoma, Renal Cell; Liver Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms | Details |
Pembrolizumab/Quavonlimab | MK-1308A | Phase 3 Clinical | Merck Sharp & Dohme Corp, Msd Ireland (Carlow) | Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Melanoma | Details |
Pembrolizumab biosimilar (biocad) | BCD-201 | Phase 3 Clinical | Biocad | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
PE0105 | PE-0105 | Phase 1 Clinical | Shanghai Yunyi Health Technology Development Co Ltd | Solid tumours; Neoplasms | Details |
Peresolimab | LY-3462817 | Phase 2 Clinical | Eli Lilly And Company | Arthritis, Rheumatoid; Autoimmune Diseases; Connective Tissue Diseases; Joint Diseases; Immune System Diseases; Psoriasis; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis | Details |
Ezabenlimab | BI-754091 | Phase 2 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Head and Neck Neoplasms; Solid tumours; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma | Details |
Izuralimab | XmAb-23104; XmAb-104 | Phase 2 Clinical | Xencor Inc | Nasopharyngeal Carcinoma; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Endometrial Neoplasms; Colorectal Neoplasms; Sarcoma; Breast Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms | Details |
AZD-7789 | AZD-7789 | Phase 2 Clinical | AstraZeneca Ag | Hodgkin Disease; Carcinoma, Non-Small-Cell Lung | Details |
PD-1 knockout engineered T cells (Anhui Kedgene Biotechnology) | Phase 2 Clinical | Anhui Korton Biological Technology Co Ltd, Hangzhou Cancer Hospital | Esophageal Neoplasms; Carcinoma, Hepatocellular | Details | |
Lorigerlimab | MGD-019; AEX1344 | Phase 2 Clinical | Macrogenics Inc | Liver Neoplasms; Solid tumours; Skin Melanoma; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Neoplasm Metastasis; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
Iparomlimab/Tuvonralimab | QL-1706; PSB-205; PBS-103/PBS-105 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Lung Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
SI-B003 | SI-B003 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis; Melanoma | Details |
AZD-2936 | AZD-2936 | Phase 2 Clinical | Astrazeneca Plc | Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Pembrolizumab/Vibostolimab | MK-7684A | Phase 3 Clinical | Merck & Co Inc | Urinary Bladder Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Gallbladder Neoplasms; Endometrial Neoplasms; Cholangiocarcinoma; Ovarian Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Hematologic Neoplasms | Details |
Rulonilimab | F-520 | Phase 3 Clinical | Shandong New Time Pharmaceutical Co Ltd | Lymphoma, T-Cell, Peripheral; Solid tumours; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Transitional Cell; Neurolymphomatosis; Lymphoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
MEDI-5752 | MEDI-5752 | Phase 2 Clinical | Medimmune Llc | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Neoplasms | Details |
RO-7247669 | RO-7247669 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Liver Neoplasms; Solid tumours; Carcinoma; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
Mavezelimab/Pembrolizumab | MK-4280A; MK-4820A | Phase 3 Clinical | Msd Ireland (Carlow) Merck Sharp & Dohme Corp | Solid tumours; Carcinoma, Renal Cell; Hodgkin Disease; Small Cell Lung Carcinoma; Colorectal Neoplasms | Details |
Ivonescimab | AK-112 | Phase 3 Clinical | Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Endometrial Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular | Details | |
Recombinant human anti-PD-1 monoclonal antibody(Sumgen) | SG-001; SYSA1802 | Phase 3 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Solid tumours; Biliary Tract Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasms; Mesothelioma; Cholangiocarcinoma; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Lymphoma; Gallbladder Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Retifanlimab | INCMGA-0012; INCMGA-00012; MGA-012 | Phase 3 Clinical | Macrogenics Inc | Esophageal adenocarcinoma; Prostatic Neoplasms; Sarcoma; Lymphoma, Follicular; Breast Neoplasms; Astrocytoma; Colorectal Neoplasms; Glioma; Endometrial Neoplasms; Carcinoma, Pancreatic Ductal; Urinary Bladder Neoplasms; Carcinoma, Squamous Cell; Penile Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Endometrioid; Melanoma; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms; Anus Neoplasms; Head and Neck Neoplasms; Lymphoma, B-Cell; Ovarian Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Solid tumours; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Glioblastoma; Oligodendroglioma; Liposarcoma | Details |
LZM-009 | LZM-009 | Phase 2 Clinical | Livzon(Group) Pharmaceutical Factory | Solid tumours; Thymoma; Carcinoma, Non-Small-Cell Lung | Details |
MW-11 | MW-11; 9MW1111; 9-MW1111; 9MW-1111; 9-MW-1111 | Phase 1 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Solid tumours; Breast Neoplasms | Details |
IBI-319 | IBI-319 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Neoplasms | Details |
IBI-321 | IBI-321 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
PH-762 | PH-762 | Phase 1 Clinical | Phio Pharmaceuticals Corp | Breast Neoplasms; Melanoma | Details |
Pidilizumab | MDV-9300; CT-011 | Phase 2 Clinical | Curetech Ltd | Ovarian Neoplasms; Carcinoma, Renal Cell; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Colonic Neoplasms; Multiple Myeloma; Prostatic Neoplasms; Sarcoma; Breast Neoplasms; Colorectal Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Melanoma; Carcinoma, Hepatocellular; Hepatitis C, Chronic | Details |
ASKG-915 | ASKG-915 | Phase 1 Clinical | Askgene Pharma | Solid tumours; Neoplasms | Details |
Fidasimtamab | IBI-315 | Phase 1 Clinical | Hanmi Pharmaceutical Co Ltd, Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
Nofazinlimab | CS-1003 | Phase 3 Clinical | Cstone Pharmaceuticals | Solid tumours; Neoplasms; Lymphoma; Carcinoma, Hepatocellular | Details |
Recombinant humanized anti-PD-1 monoclonal antibody (Shanghai CP Guojian) | 609-A; SSGJ-609A; SSGJ-609-A | Phase 2 Clinical | Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd | Solid tumours; Sarcoma; Breast Neoplasms | Details |
GX-P1 | GX-P1 | Phase 1 Clinical | Genexine Inc | Autoimmune Diseases | Details |
AK-129 | AK-129 | Phase 1 Clinical | Neoplasms | Details | |
Cetrelimab | JNJ-63723283; JNJ-3283 | Phase 3 Clinical | Johnson & Johnson | Hepatitis B, Chronic; Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Prostatic Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Small Cell | Details |
Cu 64-DOTA-pembrolizumab | 64CDP | City Of Hope National Medical Center, National Cancer Institute | Details | ||
HX-009 | HX-009 | Phase 2 Clinical | Hanx Biopharmaceutical Co Ltd | Solid tumours; Liver Neoplasms; Stomach Neoplasms; Neoplasms; Lymphoma | Details |
Reozalimab | IBI-318; LY-3434172; LY3434172 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd, Eli Lilly And Company | Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular | Details |
Spartalizumab | PDR-001 | Phase 3 Clinical | Novartis Pharma Ag | Carcinoma, Pancreatic Ductal; Chordoma; Urinary Bladder Neoplasms; Uveal melanoma; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Breast Neoplasms; Sarcoma; Cholangiocarcinoma; Colorectal Neoplasms; Primary Myelofibrosis; Gastrointestinal Stromal Tumors; Bone Marrow Diseases; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Prostatic Neoplasms, Castration-Resistant; Lung Neoplasms; Lymphoma; Sarcoma, Alveolar Soft Part; Leukemia, Myeloid, Acute; Esophageal adenocarcinoma; Uterine Neoplasms; Metastatic breast cancer; Thyroid Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Adenocarcinoma; Persistent Fetal Circulation Syndrome; Carcinoma, Endometrioid; Triple Negative Breast Neoplasms; Solid tumours; Liver Neoplasms; Leukemia, Myeloid; Leukemia; Head and Neck Neoplasms; Kidney Neoplasms; Preleukemia; Hematologic Diseases; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma; Stomach Neoplasms; An | Details |
MK-3475A | MK-3475A | Phase 3 Clinical | Merck Sharp & Dohme Corp | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
BCD-217 | BCD-217 | Phase 3 Clinical | Biocad | Melanoma | Details |
Vudalimab | XmAb-20717; XmAb-717 | Phase 2 Clinical | Xencor Inc | Carcinoma, Neuroendocrine; Prostatic Neoplasms; Vulvar Neoplasms; Cholangiocarcinoma; Adenocarcinoma, Clear Cell; Colorectal Neoplasms; Astrocytoma; Carcinoma, Squamous Cell; Thymoma; Breast Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Biliary Tract Neoplasms; Nasopharyngeal Carcinoma; Prostatic Neoplasms, Castration-Resistant; Adnexal Diseases; Mesothelioma; Adenoma, Acidophil; Carcinoma, Ovarian Epithelial; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Ovarian Neoplasms; Solid tumours | Details |
This web search service is supported by Google Inc.